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Introduction: Foetal akinesia deformation sequence syndrome (FADS) is a genetically heterogeneous disorder
characterised by the combination of foetal akinesia and developmental defects which may include pterygia (joint
webbing). Traditionally multiple pterygium syndrome (MPS) has been divided into two forms: prenatally lethal (LMPS)
and non-lethal Escobar type (EVMPS) types. Interestingly, FADS, LMPS and EVMPS may be allelic e.g. each of these
phenotypes may result from mutations in the foetal acetylcholine receptor gamma subunit gene (CHRNG). Many cases
of FADS and MPS do not have a mutation in a known FADS/MPS gene and we undertook molecular genetic studies to
identify novel causes of these phenotypes.
Results: After mapping a novel locus for FADS/LMPS to chromosome 19, we identified a homozygous null mutation in
the RYR1 gene in a consanguineous kindred with recurrent LMPS pregnancies. Resequencing of RYR1 in a cohort
of 66 unrelated probands with FADS/LMPS/EVMPS (36 with FADS/LMPS and 30 with EVMPS) revealed two additional
homozygous mutations (in frame deletions). The overall frequency of RYR1 mutations in probands with FADS/LMPS
was 8.3%.
Conclusions: Our findings report, for the first time, a homozygous RYR1 null mutation and expand the range of
RYR1-related phenotypes to include early lethal FADS/LMPS. We suggest that RYR1 mutation analysis should be
performed in cases of severe FADS/LMPS even in the absence of specific histopathological indicators of RYR1-related
disease.
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Foetal akinesia deformation sequence syndrome (FADS)
is characterised by a variable combination of foetal akin-
esia, prenatal growth restriction, developmental defects
(including cleft palate, cryptorchidism, cystic hygroma,
heart abnormalities, intestinal malrotation and lung
hypoplasia), arthrogryposis and, in some cases, limb* Correspondence: erm1000@medschl.cam.ac.uk
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unless otherwise stated.pterygia, so that there is phenotypic overlap between
FADS and severe cases of multiple pterygium syndrome
(MPS) [1]. Clinically MPS can be divided into the severe
lethal form (LMPS) and the milder non-lethal Escobar
type (EVMPS). MPS is most commonly inherited as an
autosomal recessive trait though autosomal dominant
and X-linked cases are described [2-4]. Both MPS and
FADS are genetically heterogeneous and although, in
some cases, a diagnosis of a specific primary myopathy,
metabolic or neurodevelopmental disorder can be made
by clinical and pathological investigations, the under-
lying aetiology is unknown in the majority of cases [5].
Previously, we and others have reported that germline
mutations in genes encoding specific components of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lar junction may present with autosomal recessively
inherited forms of FADS, LMPS and EVMPS [6,7].
Thus mutations in CHRNG (which encodes the foetal
gamma subunit of the acetylcholine receptor) have
been associated with FADS, LMPS and EVMPS and
mutations in genes that encode other subunits that
make up the foetal acetylcholine receptor (CHRNA1,
CHRND) or regulators of AChR function (e.g. RAPSN
and DOK7) have been described in FADS/LMPS [8-10].
Interestingly, mutations in CHRNA1, CHRND, RAPSN
and DOK7 can also cause congenital myasthenia syn-
drome (CMS), a milder disorder that is characterised by
muscle fatigability and, rarely, arthrogryposis [11-13].
Identification of the underlying genetic cause of FADS/
MPS facilitates clinical management by providing (a) pre-
cise genetic diagnosis, (b) enabling accurate predictions of
recurrence risk and prognosis and (c) allowing the possi-
bility of prenatal diagnosis. However, FADS and MPS are
genetically heterogeneous and in many cases mutations in
acetylcholine receptor-related genes cannot be identified.
In order to characterise potential genetic causes of FADS/
MPS in such cases, we undertook molecular genetic inves-
tigations in cohorts of FADS, LMPS and EVMPS families
that were enriched for autosomal recessively inherited
forms of these disorders (i.e. enriched for parental consan-
guinity) and identified loss of function RYR1 mutations as
a cause of early lethal FADS/LMPS.Material and methods
Patients
66 families with features of FADS/LMPS/EVMPS and no
known underlying genetic cause were investigated. In 36
families their clinical phenotype was FADS/LMPS and in
30 the phenotype was EVMPS. Consanguinity was re-
corded in 48% of the FADS/LMPS families and 20% of
the EVMPS families. All families gave informed consent,
the study was approved by the South Birmingham Research
Ethics Committee and performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki [14].Molecular genetic analysis
Linkage analysis
A genome-wide linkage scan was carried out using the
Affymetrix 250 K Human SNP Array 5.0 on DNA from
stored foetal material of two affected siblings from a
consanguineous family affected with FADS/LMPS. This
scan excluded linkage to known FADS/LMPS genes and
an ~10 Mb prime candidate region on chromosome 19
was identified and further evaluated by typing the par-
ents and DNA from three affected foetuses with micro-
satellite markers (details on request and see Figure 1A).RYR1 sequencing
RYR1 gene sequencing was performed after amplification
of all 106 coding exons. Initially, sequencing was performed
on whole genome amplified DNA (Qiagen REPLI-g kits)
and candidate variants were then confirmed on stock
DNA samples. Flanking primers were designed from
genomic sequence 20–80 nucleotides upstream or down-
stream from encoding exons. PCR products were se-
quenced in forward and reverse orientations using standard
BigDyeR Terminator v3.1 cycle sequencing. Details of pri-
mer sequences are available on request. Sequence traces
from each of the DNAs analysed was compared to the ref-
erence sequence from the ENSEMBL database (GRCh37:
CM000681.1 - NM_000540; transcript ENST00000355481).
The segregation of sequence variants was checked in
other family members (when available) by BigDyeR Ter-
minator v3.1 sequencing. Frequency information for
RYR1 variants was sought from the NHLBI Exome vari-
ant server [http://evs.gs.washington.edu/EVS/] if avail-
able and the prediction of possible effects of any amino
acid substitution was achieved with the PolyPhen-2 tool
[http://genetics.bwh.harvard.edu/pph2/].
Histopathological analysis
Histopathological analysis was performed on tissue ob-
tained at autopsy from two fetuses of family MPS001 (12 +
6 and 14 + 0 weeks GA, respectively) and two age-matched
controls (13 + 0 and 13 + 4 weeks GA, respectively) re-
trieved from the autopsy archive of the VU University
Medical Center, Amsterdam, The Netherlands. sixum thick
formalin-fixed paraffin-embedded tissue sections were
processed according to standard protocols [15]. Histochem-
ical staining included Hematoxylin & Eosin, Gomori tri-
chrome and alizarin red S for calcium. After heat-induced
antigen retrieval in 0.01 M citrate buffer (pH6), immuno-
histochemical staining was performed with antibodies
against desmin (Abcam, 1:500), myosin heavy chain slow
(Abcam, 1:100), active caspase 3 (Dako, 1:500), CD3 (Dako,
1:250), CD20 (Dako, 1:50) and CD45 (Dako, 1:100). Immu-
noreactivity was detected with 3,3′-diaminobenzidine as
chromogen. Tissue sections were photographed using a
Leica DM6000B microscope (Leica Microsystems). Omit-
ting primary antibodies yielded no significant staining.
Ultrastructural analysis was performed on muscle tis-
sue retrieved from formalin fixed material. The tissue
was deparaffinised in xylene (60 minutes at 70°C), rehy-
drated, fixed with 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4), post-fixed in 2% osmium tet-
roxide and embedded in epoxy resin. Ultrathin sections
were stained with uranyl acetate and lead citrate and
viewed in a FEI Technai 12 electron microscope.
The pictures were acquired as TIFF files and images were
optimized for brightness and contrast using Photoshop,
version 7.0 (Adobe systems, San Jose, CA).
A B
Figure 1 A: Mapping of a consanguineous family (MPS001) with lethal multiple pterygium syndrome to RYR1. The three affected foetuses
shared a common homozygous region between 28,725,890 - 44,669,155 on chromosome 19. B: Chromatograms showing nonsense mutation
(C.6721C > T; p.Arg2242*) at exon 42 in two affected foetuses (F1 and F2) and (in heterozygous state) in the parents (Mo and Fa).
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Clinical and molecular genetic analysis in MPS001 family
Genome wide linkage analysis was performed on a
consanguineous family from The Netherlands (see Family
MPS001 in Table 1) that had had six pregnancies affected by
FADS/MPS. The proband (F2) presented was the second
pregnancy that was terminated at 12 + 6 weeks of gestation
because of an increased nuchal translucency of 9 mm, fetal
akinesia and joint contractures. There was no intrauterine
growth restriction. At post mortem examination there was a
cystic hygroma, lung hypoplasia, webbing of both elbows
and knees and arthrogryposis. The calvaria were absent due
to birth trauma however there were no skeletal abnormal-
ities (histopathology results are described below). In the
family history, the first pregnancy was terminated because
of increased nuchal translucency of 12 mm, fetal akinesia
and a unilateral club foot. Additionally, the third, fourth,
sixth and seventh pregnancy were terminated, because of
increased nuchal translucency and fetal akinesia. The fifth
pregnancy ended in an early miscarriage.
After genotyping of DNA from two affected foetuses
(first and second foetuses) by high resolution Affymetrix
SNP arrays (Genome-Wide Human SNP Array 5.0) alarge homozygous region on chromosome 19 was se-
lected for further analysis. Genotyping with microsatellite
markers (see Table 2), was then performed on parental
DNA samples and DNA from three affected pregnancies.
The additional genotyping defined the candidate autozy-
gous region as Chr19; 35108829–44484993) (see Figure 1A).
A microsatellite marker (D8S373) that mapped within
the only other candidate autozygous region >2 Mb was
demonstrated to be heterozygous in two affected foetuses
and so excluded linkage to the chromosome 8 candidate
interval (data not shown). At the time of analysis the
candidate region on chromosome 19 contained 345
known or predicted genes including the ryanodine recep-
tor 1 (skeletal) (RYR1) gene (Chr19;38924340–39078204).
RYR1 mutation analysis
Sequencing of RYR1 in an affected foetus (F2) from Family
MPS001 revealed a homozygous RYR1 nonsense mutation
(NM_000540.2(RYR1): c.6721C > T; p.(Arg2241*)). Fur-
ther analysis demonstrated that a second affected foetus
(F1) was also homozygous for c.6721C > T, whereas both
parents were heterozygous for the nonsense mutation
(see Figure 1B). Subsequently DNA from the F3, F4, F6 and
F7 were also shown to be homozygous for the mutation
Table 1 Clinical features of 66 probands in which RYR1
mutation analysis was performed
Family number Phenotype Ethnicity Consang.
MPS001 LMPS White Y
MPS002 LMPS South Asian Y
MPS003 LMPS Middle Eastern Y
MPS004 LMPS South Asian Y
MPS005 LMPS South Asian Y
MPS006 LMPS South Asian Y
MPS007 LMPS Not available N
MPS008 LMPS White N
MPS009 LMPS White N
MPS010 FADS Middle Eastern Y
MPS011 LMPS Not recorded Y
MPS012 LMPS North African Y
MPS013 LMPS White N
MPS014 LMPS South Asian Y
MPS015 LMPS White N
MPS016 LMPS Not available Y
MPS017 LMPS North African Y
MPS018 FADS White N
MPS019 LMPS White N
MPS020 LMPS White N
MPS021 LMPS South Asian Y
MPS022 FADS Middle Eastern Y
MPS023 LMPS Middle Eastern Y
MPS024 LMPS White N
MPS025 FADS Mixed race N
MPS026 FADS White N
MPS027 LMPS Not available Y
MPS028 LMPS Not available N
MPS029 FADS/LMPS Not available N
MPS030 FADS/LMPS Not available N
MPS031 LMPS White N
MPS032 LMPS White N
MPS033 LMPS White N
MPS034 EVMPS Not available Y
MPS035 EVMPS South Asian Y
MPS036 EVMPS White N
MPS037 EVMPS Not available N
MPS038 EVMPS White N
MPS039 EVMPS White N
MPS040 EVMPS White N
MPS041 EVMPS White N
MPS042 EVMPS White N
MPS043 EVMPS South Asian N
Table 1 Clinical features of 66 probands in which RYR1
mutation analysis was performed (Continued)
MPS044 EVMPS South American N
MPS045 EVMPS South Asian Y
MPS046 EVMPS South Asian Y
MPS047 EVMPS White N
MPS048 EVMPS African Y
MPS049 EVMPS Not available N
MPS050 EVMPS White N
MPS051 EVMPS White N
MPS052 EVMPS White N
MPS053 EVMPS White Y
MPS054 EVMPS White N
MPS055 EVMPS White N
MPS056 EVMPS White N
MPS057 EVMPS South American N
MPS058 EVMPS White N
MPS059 EVMPS African N
MPS060 EVMPS White N
MPS061 EVMPS White N
MPS062 EVMPS White N
MPS063 EVMPS White N
MPS064 LMPS Middle Eastern ?
MPS065 LMPS White N
MPS066 LMPS North African Y
Clinical phenotype (FADS = Foetal Akinesia Deformation Sequence, LMPS = Lethal
Multiple Pterygium Syndrome; EVMPS = Escobar Variant Multiple Pterygium
Syndrome), ethnic origin and presence of parental consanguinity is recorded).
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viously detected (rs200563280), in the heterozygous state in
1 of 6503 individuals genotypes listed in the exome variant
server (http://evs.gs.washington.edu/EVS) (no homozygous
genotypes were detected at an average read depth of 49). In
order to assess the potential role of recessive RYR1 mu-
tations in FADS, and/or MPS we proceeded to screen a
further 66 probands for germline RYR1 variants. Two
further potential candidate homozygous mutations were
detected, a novel in-frame deletion of 27 nucleotides
(NM_000540.2(RYR1): c.2097_2123del p.(Glu699_Gly707-
del)) and an in-frame deletion of 3 nucleotides c.7043del-
GAG p.(Glu2347del) (rs121918596)) (see Table 3). Each of
the candidate mutations were detected in the homozygous
state in individuals with FADS/MPS.
Clinical and molecular genetic analysis in MPS002 family
A novel in-frame deletion of 27 nucleotides (NM_000540.2
(RYR1):c.2097_2123del p.(Glu699_Gly707del)) was detected
in Family MPS002 of Pakistani origin (Figure 2A).
The family presented at eighteen weeks of pregnancy
with a female foetus with bilateral talipes and fixed flexion
Table 2 Microsatellite markers employed in Mapping of chromosome 19 candidate region in consanguineous family
(MPS001)
Marker Genomic position Source
D19S222 Chr.19-28,725,890-28,726,217 bp http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1341900
D19S433 Doesn’t map to Chr.19 assembly http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1298168
D19S430 Chr.19-32,302,451-32,302,741 bp http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1657125
D19S224 Chr.19-35,493,932-35,494,196 bp http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1336138
Chr19r2-15xAC41 Chr.19-41,435,658-43,123,394 ftp://ftp.broad.mit.edu/pub/human_STS_releases/
D19S220 cHR.19-34,8798,595-34,879,871 BP http://rgd.mcw.edu/rgdweb/search/markers.html?term=D19S220&speciesType=1
D19S228 Chr.19-34,937,645-34,937,798 bp http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1338234
D19S421 Chr.19-38,871,106-38,871,460 bp http://rgd.mcw.edu/rgdweb/report/marker/main.html?id=1337182
Chr19R2-15xTAT Chr.19-44,221,282-44,669,155 ftp://ftp.broad.mit.edu/pub/human_STS_releases/
Chr19r2-22xGT44 Chr.19-44,221,282-44,669,155 ftp://ftp.broad.mit.edu/pub/human_STS_releases/
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ultrasound scan including a large cystic hygroma, sub-
cutaneous oedema, ascites also pleural and pericardial
effusions. A cardiac ventriculoseptal defect was also
suspected. The pregnancy was terminated at 19 weeks of
gestation. Post mortem examination revealed no intrauter-
ine growth restriction, but the foetus was considered to be
dysmorphic (protuberant eyes, hypertelorism, a flat nose,
low set ears), with a complete cleft palate. There was fixed
flexion of all the limb joints and a fracture of the proximal
left humerus. Pterygia were present between the inferior
margin of the mandible and the anterior chest wall and
across the elbows. The heart was normal. There were no
other congenital abnormalities noted. The brain was struc-
turally and histologically normal. Muscle histopathological
analysis is described below.
This candidate RYR1 c.2097_2123del mutation was
present in a homozygous state in two affected foetuses
and was found to be heterozygous in both parents. The
in-frame deletion was predicted to result in a missense
substitution (p.(Glu699Asp)) followed by a deletion of 9
amino acids (GlyTrpGlyGlyAsnGlyValGlyAsp) from the
SPRY2 domain of the RYR1 gene product. All 9 of these
deleted amino acids were conserved in vertebrate RYR1
orthologues including zebrafish and 6 of 9 amino acids
were conserved in C.elegans (see Figure 2A).
Clinical and molecular genetic analysis in MPS003 family
In a consanguineous family (MPS003) with LMPS, a
homozygous in-frame deletion (NM_000540.2(RYR1):Table 3 Rare RYR1 variants detected in families with FADS/LM
Family ID DNA change Protein change
MPS001 c.6721C > T p.Arg2241STOP
MPS002 c.2097_2123del p.(Glu699_Gly707d
MPS003 c.7043delGAG p.(Glu2347del))c.7043delGAG, p.(Glu2347del) (rs121918596)) was iden-
tified in exon 45 in the proband (Figure 2B). This female
foetus was the third pregnancy of a consanguineous
Palestinian couple. In the pregnancy there was a sugges-
tion of polyhydramnios. On ultrasound examination there
were reduced foetal movements and joint contractures
were present. The foetus had a cystic hygroma, a hydro-
thorax, a short neck, a kyphosis and a short trunk due to a
scoliosis. The pregnancy was terminated at 23 + 3 weeks
of gestation. On examination there was no evidence of
intrauterine growth restriction. The foetus had craniofacial
anomalies including downslanting palpebral fissures,
hypertelorism, a broad nasal bridge, a small mouth and
high arched palate, low set ears, a short broad neck and a
scoliosis. There were flexion contractures of the shoulders,
elbows, wrists, hips, knees and ankles. There were
clenched hands but no finger contractures. There was
webbing of the axillae, elbows, hips, knees and ankles, and
rocker bottom feet. There was a severe scoliosis but no
bony abnormalities identified on the radiograph. There
was pulmonary hypoplasia. There were no abnormalities
of the brain or spinal cord. The muscle in the extremities
showed increased fibre size disproportion on microscopy
(Figure 3). Cardiac muscle histology was normal.
The karyotype was normal. CHRNG, CHRNA1,
CHRNB1, CHRND, RAPSN and DOK7 analysis was
normal. Subsequently a fourth pregnancy of a male foetus
was terminated at 21 + 3 weeks of pregnancy because of
evidence of foetal akinesia. On examination of the foetus
no growth restriction was noted. There was a cysticPS phenotypes





Figure 2 Identification of RYR1 in frame deletions. A. In the proband (F1) from Family MPS002 there is a homozygous deletion of 27 nucleotides
(c.2097-2123del). The deleted/altered amino acids exhibited total conservation in zebrafish and partial conservation with 6/9 amino acids in C. elegans
conserved. B: In the proband (F1) from Family MPS003 there is a homozygous deletion of 3 nucleotides (c.7043delGAG). The deleted amino
acids (Glu/E) was conserved in the zebrafish with some degree of functional conservation in C.elegans (D/E).
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a broad nasal bridge, a small mouth with a high arched
palate. There were contractures of the large and small
joints with webbing of the axillae, elbows, hips and knees
with pronounced kyphosis, 11 pairs of ribs, but no other
bony abnormalities on radiography.
The foetus had lung hypoplasia and there was a small
atrial septal defect. There were no abnormalities of the
brain or spinal cord. Skeletal muscle microscopy showed
increased fibre disproportion. Immunohistology of the
structural proteins (alpha-actin, dystrophin 1,2 and 3,
alpha, beta, delta, and gamma sarcoglycan, alpha and
beta dystroglycan, dysferlin, caveolin-3, merosin laminin
alpha-2 chain, merosin M-chain, myosin heavy chain
and spectrin-1) did not identify the pathogenesis of the
myopathy (data not shown). It was concluded that the
foetus had a non specific myopathy. The couple had one
miscarriage and they had an older daughter with a severe
undiagnosed metabolic disorder. There were no instances
of malignant hyperthermia in the family and the mother
had general anaesthesia on several occasions without anyproblems. The RYR1 c.7043delGAG candidate mutation
was present in both parents in the heterozygous state and
there were no other relatives available for analysis. The
c.7043delGAG deletion is predicted to result in loss of a
glutamic acid residue at codon 2347 in the MHS/CCD
hotspot region 2 of the RYR1 gene product (Figure 4). This
residue is conserved in zebrafish and although the amino
acid sequence around this residue is divergent in C. ele-
gans, the glutamic acid is conserved. Polymorphic vari-
ation at codon 2347 was not present in >13,000 RYR1
alleles reported on the exome variant server (http://evs.gs.
washington.edu/EVS), but the c.7043delGAG deletion was
previously described, in the heterozygous state, in affected
members (total 5 cases) of two unrelated families that pre-
sented with malignant hyperthermia [16].
Histopathological studies
Family MPS001
Histopathological analysis was performed on intercostal
skeletal muscle from the two foetuses of family MPS001
and two age-matched controls, as this was the only
Figure 3 MPS001: Histological and ultrastructural findings in RYR1-mutant fetal skeletal muscle. (A,B) Hematoxilin & Eosin stain shows
increased fiber size variability in the RYR1-mutant muscle (A, foetus F1) compared to an age-matched control (B). Some RYR1-mutant fibres have
intensely eosinophilic cytoplasm (A, arrows). The nuclei are localized centrally in all fibres, compatible with the gestational age. The perinuclear
clear halo present in many fibres is an artefact due to formalin fixation. (C,D) Labelling against desmin reveals a similar pattern of immunoreactivity and
no evident core-like structures in both RYR1-mutant (C, foetus F1) and control tissue (D). (E-H) Labelling against the myosin heavy chain fast (E,F) and
slow (G,H) shows that the numbers of myosin fast-positive type II fibres is comparable between the patient (E, foetus F2) and the control (F), whereas
myosin slow-positive type I fibres are markedly reduced in RYR1-mutant (G, foetus F2) compared to control muscle (H). (I) Labelling for active caspase
3 is negative, excluding apoptosis, also in atrophic RYR1-mutant muscle fibres (foetus F2). (J) Alizarin red S staining shows no detectable accumulation
of calcium inside the RYR1-mutant muscle fibres (foetus F1). (K,L) Ultrastructural analysis reveals profound myofibrillar disarray with disappearance of
the Z-bands in the RYR1-mutant muscle fibres (K, foetus F2). By contrast, Z-bands are easily detected in control tissue (L). Magnifications: (A-J) 400x; K,L
30000x. (lower panels): histological findings in RYR1-mutant (Family MPS003) foetal skeletal muscle, GA 23 weeks. (M,N) Hematoxilin & Eosin
stain of formalin fixed and paraffin embedded psoas muscle shows loss of fibres with increased fibre size variability and mild fibrosis in the
RyR1-mutant muscle (M,N) compared to an age-matched control (O).
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examination showed marked structural abnormalities in
the RYR1-mutant skeletal muscle, including fibre loss,
increased fibre size variability and increased endomysial
spacing with fibrosis (Figure 3A,B). In agreement with the
gestational age, muscle fibres of both patients and controls
contained centrally positioned nuclei. Sparse muscle fibres
with intense eosinophilic cytoplasm were detected in thepatients, but not in the controls (Figure 3A,B) which was
not due to calcium accumulation (Figure 3J). Staining
against desmin, an intermediate filament protein typically
expressed in muscle tissue, revealed no core-like struc-
tures (Figure 3C,D). Fibre type distribution, assessed by
staining against the slow and fast myosin heavy chain,
showed a marked reduction of myosin slow immunoreac-
tivity, suggesting preferential hypotrophy of type I fibres
Figure 4 Location of nonsense mutation in MPS001 (X) and in frame deletions in Family MPS002 (red triangle) and Family MPS003
(black triangle) in relation to exon structure and RYR1 protein domains. Malignant Hyperthermia/central core disease mutation hot spots
shown as stippled boxes, SPRY2 interacting domains 1,2 & 3 as grey boxfibres, Homer binding motifs as hatched boxes.
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apoptotic loss of muscle fibres (Figure 3I). Ultrastructural
analysis demonstrated hypotrophy with profound myofi-
brillar disarray and Z-disc loss (Figure 3K,L). Analysis of
the spinal cord showed no loss of motor neurons or other
pathological signs in the anterior horns and most proximal
segments of the motor nerves, supporting the myogenic
nature of the histological and ultrastructural findings.
Family MPS003
The muscle appearance was striking but non-specific.
There was variation in myofibre size with larger hyali-
nised rounded fibres and smaller rounded atrophic fibres
with an apparent increase in fibrous tissue. Fast and slow
myosin heavy chains were co-expressed in a proportion
of foetal myofibres. Occasional scattered chronic inflam-
matory cells were confirmed on CD3 and CD20 staining.
Additional CD45 staining was interpreted as non-specific.
Gomori trichrome staining was negative for nemaline rods
and ragged red fibres. The couple had a previous intra-
uterine death at 23 weeks of gestation of a similarly
affected male foetus (Figure 3M-O).
Discussion
After undertaking genetic linkage studies in a consan-
guineous family with recurrent FADS/LMPS we mapped
a large candidate autozygous region to chromosome 19
and then proceeded to identify a homozygous nonsense
mutation in the ryanodine receptor 1 (RYR1) gene. RYR1
encodes the largest known ion channel and the 2.3 MDa
homotetrameric ryanodine receptor 1 structure is formed
from the 565 kDa RYR1 component proteins. Though the
large size (15.3 kb coding sequence in 106 exons) of the
RYR1 gene makes mutation analysis challenging, RYR1
mutations have previously been described in a variety of
human disease phenotypes. Thus initially RYR1 mutations
were described in individuals susceptible to malignanthyperthermia (MHS) [17,18]. RYR1 mutations associated
with MHS are typically heterozygous missense substi-
tutions [19-21]. Subsequently RYR1 mutations were
described in the context of a variety of histological sub-
types of congenital myopathies including central core
disease, minicore/centronuclear myopathy with external
ophthalmoplegia, centronuclear myopathy and congeni-
tal fibre-type disproportion [22-24]. Both dominant and
recessive forms of RYR1-related congenital myopathies
have been described and genotype-phenotype correlations
have provided insights into likely clinical-functional rela-
tionships. Thus, in a large cohort of RYR1-associated
myopathies, dominant mutations tended to be associated
with milder phenotypes whereas recessively inherited
cases had an earlier onset and a more severe course
[25-27]. In addition, though the age at presentation of
recessive RYR1 myopathies is variable, in a recent series all
presented before age 10 years. Whereas RYR1 mutations
in dominantly inherited disease tend to cluster in specific
protein domains e.g. C-terminal region (amino acids
4,550-4,940) in central core disease and N-terminal re-
gions (amino acids 35–614 and 2,163-2,458) with MHS,
recessively inherited mutations are widely distributed
throughout the protein [25,27]. Typically the mutations
found in patients with recessively inherited RYR1-myop-
athies are a combination of null mutation with a missense
mutation, though two missense mutations can occur.
Thus in a series of 118 patients with RYR1-related reces-
sively inherited myopathies from four recent reports
[25,27-30], 61.5% of the cases had a truncating/in frame
deletion/splice site mutation in combination with a
missense mutation and 38.1% harboured two missense
mutations. It is therefore striking that we identified a
homozygous null mutation in affected individuals from
Family MPS001. This observation is consistent with (a)
our previous observation for RAPSN that homozygosity
for a null mutation can cause FADS/LMPS other
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tion can cause a milder phenotype, (b) that mice homo-
zygous for a Ryr1 mutation die in the perinatal period
with gross abnormalities of skeletal muscle [31] and (c)
a history of foetal akinesia may be found with early on-
set autosomal recessive RYR1-related congenital myop-
athies [25]. In addition, Romero et al. [32] reported seven
foetuses/infants from six unrelated families affected by
central core disease in whom there was a history of foetal
akinesia [33]. Four cases from three families were found
to harbour RYR1 mutations: three cases (from two families)
were compound heterozygotes for RYR1 missense muta-
tions and in one case only a heterozygous missense
mutation was detected. Three of the four cases pre-
sented at birth and though in one case the foetus died at
32 weeks gestation (following termination of pregnancy
after a previously affected sibling). Thus the phenotype
in these cases was less severe than we observed and our
findings demonstrate that the association between RYR1
mutations and foetal akinesia extends to severe early
onset lethal FADS and that histopathological evidence
of central core disease is not a prerequisite for molecu-
lar investigation of RYR1 in foetal akinesia.
The overall frequency of RYR1-related disease in our
FADS/LMPS/EVMPS cohort was 4.5% (3/66; 95% CI: 0
to 9.5%) and 8.3% (3/36; 95% CI 0 to 19.5%) in our
FADS/LMPS cohort. The case for pathogenicity of the
two in frame deletions is supported by their absence
from large repositories of genetic variation in control
individuals, segregation with disease within the relevant
families and evolutionary conservation of the mutated/
deleted amino acid residues. RYR1 is a key component of
the excitation-coupling process in skeletal muscle such
that opening of RYR1 channels result in release of Ca2+
from the sarcoplasmic reticulum and initiation of muscle
contraction. The novel in-frame deletion of 27 nucleotides
(c.2097_2123del p.(Glu699_Gly707del)) detected in Family
MPS002 is predicted to result in a missense substitution
(p.E699N) followed by a deletion of 9 amino acids
(GWGGNGVGD) within the SPRY2 predicted protein-
protein interaction motif [32] (highlighted in Figure 4).
Previously missense substitutions within or adjacent to this
deletion (c.2113G >C; p.Gly705Arg and p.Asp708Asn) have
been reported in recessively inherited myopathies [25].
The exon 45 in-frame deletion (c.7043delGAG) identi-
fied in Family MPS003 was predicted to result in loss
of a glutamic acid residue at codon 2347. A missense
mutation at a nearby residue (p.Arg2355Trp) has been
reported in both dominantly and recessively inherited
myopathies [20] and it is interesting that this deletion
was previously described in the heterozygous state, in
two unrelated families with malignant hyperthermia [34].
p.Glu2347 is contained within the MHS/CCD mutation
hotspot in N-terminal region 2 (stippled box Figure 4),[16]. Though no history of malignant hyperthermia syn-
drome was reported in Family MPS003, incomplete
penetrance is well recognised in malignant hyperther-
mia and mutation carriers may not have been exposed
to trigger events.
Though our findings establish recessive RYR1 muta-
tions as a cause FADS/LMPS, further work is required
to fully establish the frequency of RYR1 mutations in
FADS/LMPS cohorts and to address how novel missense
or in-frame deletions/insertions might be reliably inter-
preted in a clinical diagnostic setting. In a recent review
of congenital myopathies treated at a single referral
centre, a genetic diagnosis was established in two-thirds
of cases and almost 60% of those with a genetic diagno-
sis had a RYR1-related myopathy [27]. Our findings sug-
gest that RYR1-related neuromuscular disease may be a
significant cause of FADS/LMPS. Though recessively
inherited RYR1-related myopathies have been associated
with certain histopathological subtypes such as minicore,
centronuclear and congenital fibre-type disproportion
myopathies, RYR1 mutations may be associated with
other histological subtypes or only nonspecific myo-
pathic features [27]. Extrapolating from these observa-
tions, we suggest that, in cases of FADS/LMPS, RYR1
mutation should be performed as part of a multigene
diagnostic strategy (e.g. by second generation sequencing
analysis) rather than being specifically targeted to cases
with histopathological features that are considered char-
acteristic of a RYR1-associated myopathy. The identifica-
tion of RYR1 mutations as a cause of familial LMPS/
foetal akinesia enables accurate reproductive risk prediction
and reproductive options including prenatal diagnosis and
pre-implantation diagnosis but also might lead to the
identification of relatives at risk of malignant hyperthermia.
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